Page last updated: 2024-08-21

psilocybin and Depression, Involutional

psilocybin has been researched along with Depression, Involutional in 58 studies

Research

Studies (58)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (3.45)	24.3611
2020's	56 (96.55)	2.80

Authors

Authors	Studies
Figiel, M; Kozlowska, U; Nichols, C; Wiatr, K	1
Chen, WN; Hu, YR; Li, NX; Zhang, B	1
Barker, PB; Barrett, FS; Davis, AK; Doss, MK; Finan, PH; Griffiths, RR; Pekar, JJ; Považan, M; Rosenberg, MD; Sepeda, ND; Smith, GS	1
Castle, D; Ceban, F; Gill, H; Ho, R; Lee, Y; Lin, K; Ling, S; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Teopiz, KM	1
Agin-Liebes, G; Davis, AK	1
Bird, C; Carter, B; Day, C; Jafari, H; Knight, G; Mantingh, T; Modlin, NL; Reinholdt, F; Rucker, J; Young, A	1
Gold, JA; Pearson, C; Siegel, J	1
Jones, GM; Nock, MK	1
Jordens, C; Miceli McMillan, R	1
Barrett, FS; Cosimano, MP; Davis, AK; Griffiths, RR; Gukasyan, N; Johnson, MW; Sepeda, ND	1
Hillhouse, TM; Magaraggia, I; Porter, JH; Schreiber, R; van den Berg, M	1
Carhart-Harris, R; Daws, RE; Erritzoe, D; Giribaldi, B; Nutt, D; Roseman, L; Sexton, JD; Timmermann, C; Wall, MB	1
Dörner, S; Hertweck, C; Hoffmeister, D; Lenz, C; Sherwood, A; Trottmann, F	1
Castle, D; Cha, DS; Gill, B; Gill, H; Mansur, RB; Marks, CA; McIntyre, RS; Patel, P; Puramat, P; Rodrigues, NB; Rosenblat, JD	1
Jairaj, C; Rucker, JJ	1
Carhart-Harris, R; Gandy, S; Geerts, D; Kaelen, M; Kartner, L; Kettner, H; Mertens, L; Nour, MM; Nutt, D; Roseman, L; Timmermann, C; Watts, R	1
Abbar, M; Becamel, C; Conejero, I; Lopez-Castroman, J; Prouzeau, D; Voyvodic, PL	1
Ameringen, MV; Beaulieu, S; Castle, D; Frey, BN; Garel, N; Greenway, KT; Husain, MI; Kennedy, SH; Lam, RW; Lee, Y; Mansur, RB; McIntyre, RS; Milev, R; Offman, H; Parikh, SV; Ravindran, AV; Rosenblat, JD; Schaffer, A; Taylor, V; Tourjman, V; Yatham, LN	1
Cleare, AJ; Ko, K; Kopra, EI; Rucker, JJ	1
Jones, GM	1
Aaronson, ST; Alvarez, O; Arden, PC; Baker, A; Bennett, JC; Bird, C; Blom, RE; Brennan, C; Brusch, D; Burke, L; Campbell-Coker, K; Carhart-Harris, R; Cattell, J; Daniel, A; DeBattista, C; Dunlop, BW; Eisen, K; Feifel, D; Forbes, M; Goodwin, GM; Haumann, HM; Hellerstein, DJ; Hoppe, AI; Husain, MI; Jelen, LA; Kamphuis, J; Kawasaki, J; Kelly, JR; Key, RE; Kishon, R; Knatz Peck, S; Knight, G; Koolen, MHB; Lean, M; Licht, RW; Malievskaia, E; Maples-Keller, JL; Mars, J; Marwood, L; McElhiney, MC; Miller, TL; Mirow, A; Mistry, S; Mletzko-Crowe, T; Modlin, LN; Nielsen, RE; Nielson, EM; O'Keane, V; Offerhaus, SR; Páleníček, T; Printz, D; Rademaker, MC; Reinholdt, F; Repantis, D; Rucker, J; Rudow, S; Ruffell, S; Rush, AJ; Schoevers, RA; Seynaeve, M; Shao, S; Soares, JC; Somers, M; Stansfield, SC; Sterling, D; Strockis, A; Tsai, J; van Reemst, A; Visser, L; Wahba, M; Williams, S; Young, AH; Ywema, P; Zisook, S	1
Hoffmeister, D; Kramer, K; Rupp, B; Schäfer, T; Werten, S	1
Barber, G; Nemeroff, CB; Siegel, S	1
Agrawal, M; Ameli, R; Berger, A; Shnayder, S; Sinaii, N	1
Aaronson, ST; Kirlic, N; Lennard-Jones, M; Miller, TM; Modlin, NL; Rucker, JJ; Schlosser, D	1
Aaronson, ST; Alvarez, O; Atli, M; Bennett, JC; Croal, M; DeBattista, C; Dunlop, BW; Feifel, D; Goodwin, GM; Hellerstein, DJ; Husain, MI; Kelly, JR; Lennard-Jones, MR; Licht, RW; Malievskaia, E; Marwood, L; Mistry, S; Páleníček, T; Redjep, O; Repantis, D; Schoevers, RA; Septimus, B; Simmons, HJ; Soares, JC; Somers, M; Stansfield, SC; Stuart, JR; Tadley, HH; Thiara, NK; Tsai, J; Wahba, M; Williams, S; Winzer, RI; Young, AH; Young, MB; Zisook, S	1
Hieronymus, F; Østergaard, SD	1
Benyamina, A; Dervaux, A; Roméo, B	1
Courtet, P; Lengvenyte, A; Olié, E	1
Goodwin, GM; Hellerstein, DJ; Young, AH	1
Ibi, D	1
Baumann, MH; Belouin, SJ; Berger, A; Dworkin, RH; Ghauri, MH; Hendricks, PS; Henningfield, JE; Lanier, RK; Ross, S; Zia, FZ	1
Agrawal, M; Emanuel, E; Richards, B; Richards, W; Roddy, K; Thambi, P	1
Carhart-Harris, RL; Erritzoe, D; Giribaldi, B; Nutt, DJ; Weiss, B	1
Castle, DJ; Meikle, SE; Rossell, SL; Williams, ML	1
Carhart-Harris, RL; Monson, CM; Wagner, AC; Zeifman, RJ	1
Belouin, SJ; Heal, DJ; Henningfield, JE; Smith, SL	1
Beck, A; Byrne, K; Durns, T; Garland, EL; Hendrick, J; Lewis, BR; Thielking, P	1
Chen, J; Chen, T; Cheng, L; Liu, H; Liu, Z; Ma, J; Pi, C; Shen, H; Tang, J; Wei, Y; Xiong, L; Yuan, J; Zhang, X; Zhao, L; Zhong, Y; Zuo, Y	1
D'Souza, DC; Pathania, S; Pittman, B; Safi-Aghdam, H; Skosnik, PD; Sloshower, J; Syed, S	1
Chen, MH; Su, TP; Tu, PC	1
Croal, M; Feifel, D; Goodwin, GM; Kelly, JR; Malievskaia, E; Marwood, L; Mistry, S; O'Keane, V; Peck, SK; Simmons, H; Sisa, C; Stansfield, SC; Tsai, J; Williams, S	1
Bradley, E; Brown, C; Brown, RT; Davis, MC; Dunlop, BW; Gapasin, T; Griffiths, RR; Gukasyan, N; Hassman, M; Heinzerling, K; Hu, X; Hutson, PR; Kakar, R; Kelly, DF; Kelmendi, B; Lenoch, K; Linton, W; Mletzko, T; Nayak, SM; Nelson-Douthit, C; Nicholas, CR; O'Donnell, KC; Penn, AD; Raison, CL; Robison, R; Ross, S; Sanacora, G; Sloshower, J; Tarpley, G; Trivedi, RP; Utzinger, M; Warchol, K; Wilson, S; Woolley, J	1
Chen-Li, DCJ; Fancy, F; Haikazian, S; Husain, MI; Johnson, DE; Levinta, A; Mansur, RB; McIntyre, RS; Rosenblat, JD	1
Fricke, J; Hoffmeister, D; Kargbo, R; Lenz, C; Peschel, G; Regestein, L; Rosenbaum, MA; Sherwood, A	1
Andersen, KAA; Carhart-Harris, R; Erritzoe, D; Nutt, DJ	1
Barrett, FS; Cosimano, MP; Davis, AK; Finan, PH; Griffiths, RR; Johnson, MW; May, DG; Sepeda, ND	1
Reynolds, CF	1
Donovan, LL; Hansen, HD; Issazadeh-Navikas, S; Jaberi, E; Johansen, JV; Johansen, SS; Knudsen, GM; Linnet, K; Ozenne, B; Ros, NF	1
de Manincor, M; Galvão-Coelho, NL; Gonzalez, M; Marx, W; Perkins, D; Sarris, J; Sinclair, J	1
Davis, AK; Griffiths, RR	1
Bouso, JC; Dos Santos, RG; Hallak, JEC; Ona, G	1
Baker-Jones, M; Blemings, A; Carhart-Harris, R; Erritzoe, D; Giribaldi, B; Martell, J; Murphy, R; Murphy-Beiner, A; Nutt, DJ; Watts, R	1
Kuiperes, Z; Magaraggia, I; Schreiber, R	1
Benitah, K; Gill, H; Lipsitz, O; Lui, LMW; McIntyre, RS; Meshkat, S; Rosenblat, JD; Siegel, AN; Teopiz, KM	1
Bird, CIV; Modlin, NL; Rucker, JJH	1
Florova, G; Girard, RB; Idell, RD; Idell, S; Komissarov, AA; Shetty, S	1

Reviews

19 review(s) available for psilocybin and Depression, Involutional

Article	Year
From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders. Journal of neurochemistry, 2022, Volume: 162, Issue:1 Topics: Depressive Disorder, Major; Hallucinogens; Humans; Neurodegenerative Diseases; Neurology; Psilocybin; Psychiatry; Substance-Related Disorders	2022
Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis. Journal of affective disorders, 2022, 01-01, Volume: 296 Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Psilocybin	2022
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression. CNS drugs, 2022, Volume: 36, Issue:1 Topics: Antidepressive Agents; Brain; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Psilocybin	2022
Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history. Journal of the neurological sciences, 2022, Mar-15, Volume: 434 Topics: Depression; Depressive Disorder, Major; Hallucinogens; Humans; Psilocybin; Psychotherapy	2022
The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies. Psychiatry research, 2022, Volume: 313 Topics: Adult; Amygdala; Depressive Disorder, Major; Hallucinogens; Humans; Magnetic Resonance Imaging; Neuroimaging; Psilocybin	2022
Postpartum depression: A role for psychedelics? Journal of psychopharmacology (Oxford, England), 2022, Volume: 36, Issue:8 Topics: Depression, Postpartum; Depressive Disorder, Major; Female; Hallucinogens; Humans; Mothers; Psilocybin	2022
Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review. Current psychiatry reports, 2022, Volume: 24, Issue:10 Topics: Antidepressive Agents; Depressive Disorder, Major; Hallucinogens; Humans; Psilocybin	2022
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2023, Volume: 68, Issue:1 Topics: Anxiety; Canada; Depressive Disorder, Major; Hallucinogens; Humans; Neoplasms; Psilocybin	2023
Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis. Journal of affective disorders, 2023, 02-01, Volume: 322 Topics: Depression; Depressive Disorder, Major; Hallucinogens; Humans; Lysergic Acid Diethylamide; Psilocybin	2023
[Contribution of serotonin 5-HT Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2023, May-01, Volume: 158, Issue:3 Topics: Antidepressive Agents; Depressive Disorder, Major; Hallucinations; Hallucinogens; Humans; Ketamine; Psilocybin; Receptor, Serotonin, 5-HT2A; Serotonin	2023
Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs. Neuropharmacology, 2023, 08-01, Volume: 233 Topics: Chronic Pain; Depressive Disorder, Major; Hallucinogens; Humans; Lysergic Acid Diethylamide; Psilocybin; Quality of Life; United States	2023
Molecular mechanisms of rapid-acting antidepressants: New perspectives for developing antidepressants. Pharmacological research, 2023, Volume: 194 Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Disease Models, Animal; Ketamine; Mice; Psilocybin; Receptors, N-Methyl-D-Aspartate	2023
Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. Psychiatry research, 2023, Volume: 329 Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Hallucinogens; Humans; Psilocybin; Psychotherapy	2023
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Acta psychiatrica Scandinavica, 2021, Volume: 143, Issue:2 Topics: Alcoholism; Anxiety Disorders; Depressive Disorder, Major; Hallucinogens; Humans; Psilocybin	2021
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. Psychopharmacology, 2021, Volume: 238, Issue:2 Topics: Affect; Banisteriopsis; Depression; Depressive Disorder, Major; Double-Blind Method; Hallucinogens; Healthy Volunteers; Humans; Lysergic Acid Diethylamide; Mood Disorders; Psilocybin; Randomized Controlled Trials as Topic; Serotonin Receptor Agonists; Treatment Outcome	2021
Psychedelic Medicines in Major Depression: Progress and Future Challenges. Advances in experimental medicine and biology, 2021, Volume: 1305 Topics: Depression; Depressive Disorder, Major; Hallucinogens; Humans; Psilocybin; Psychiatry	2021
Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach. Neurobiology of learning and memory, 2021, Volume: 183 Topics: Anhedonia; Cognitive Dysfunction; Depressive Disorder, Major; Hallucinogens; Hippocampus; Humans; Neuronal Plasticity; Prefrontal Cortex; Psilocybin	2021
Registered clinical studies investigating psychedelic drugs for psychiatric disorders. Journal of psychiatric research, 2021, Volume: 139 Topics: Alcoholism; Depressive Disorder, Major; Hallucinogens; Humans; Pharmaceutical Preparations; Psilocybin	2021
Psilocybin and MDMA for the treatment of trauma-related psychopathology. International review of psychiatry (Abingdon, England), 2021, Volume: 33, Issue:3 Topics: Depressive Disorder, Major; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin; Stress Disorders, Post-Traumatic; Treatment Outcome	2021

Trials

11 trial(s) available for psilocybin and Depression, Involutional

Article	Year
Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial. BMJ open, 2021, 12-01, Volume: 11, Issue:12 Topics: COVID-19; Depressive Disorder, Major; Feasibility Studies; Humans; Psilocybin; Randomized Controlled Trials as Topic; SARS-CoV-2; Treatment Outcome	2021
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of psychopharmacology (Oxford, England), 2022, Volume: 36, Issue:2 Topics: Adult; Aged; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder, Major; Female; Follow-Up Studies; Hallucinogens; Humans; Male; Middle Aged; Prospective Studies; Psilocybin; Psychiatric Status Rating Scales; Psychotherapy; Time Factors; Treatment Outcome; Young Adult	2022
Increased global integration in the brain after psilocybin therapy for depression. Nature medicine, 2022, Volume: 28, Issue:4 Topics: Antidepressive Agents; Brain; Depression; Depressive Disorder, Major; Double-Blind Method; Escitalopram; Hallucinogens; Humans; Psilocybin	2022
The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world. Psychopharmacology, 2022, Volume: 239, Issue:11 Topics: Depressive Disorder, Major; Emotions; Hallucinogens; Humans; Psilocybin; Surveys and Questionnaires	2022
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. The New England journal of medicine, 2022, 11-03, Volume: 387, Issue:18 Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Psilocybin; Treatment Outcome	2022
Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of affective disorders, 2023, 04-14, Volume: 327 Topics: Anxiety; Depression; Depressive Disorder, Major; Humans; Patient Reported Outcome Measures; Psilocybin; Quality of Life	2023
How does psilocybin therapy work? An exploration of experiential avoidance as a putative mechanism of change. Journal of affective disorders, 2023, 08-01, Volume: 334 Topics: Anxiety; Anxiety Disorders; Depressive Disorder, Major; Humans; Psilocybin; Treatment Outcome	2023
Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms. Journal of psychopharmacology (Oxford, England), 2023, Volume: 37, Issue:7 Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Electroencephalography; Hallucinogens; Humans; Neuronal Plasticity; Psilocybin	2023
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2023, Volume: 48, Issue:10 Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Psilocybin; Treatment Outcome	2023
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA psychiatry, 2021, 05-01, Volume: 78, Issue:5 Topics: Adult; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder, Major; Female; Follow-Up Studies; Hallucinogens; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Patient Acuity; Psilocybin; Psychotherapy; Time Factors; Young Adult	2021
Trial of Psilocybin versus Escitalopram for Depression. The New England journal of medicine, 2021, 04-15, Volume: 384, Issue:15 Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Hallucinogens; Humans; Male; Middle Aged; Psilocybin; Self Report; Surveys and Questionnaires; Young Adult	2021

Other Studies

28 other study(ies) available for psilocybin and Depression, Involutional

Article	Year
Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Translational psychiatry, 2021, 11-08, Volume: 11, Issue:1 Topics: Brain Mapping; Cognition; Depressive Disorder, Major; Humans; Magnetic Resonance Imaging; Psilocybin	2021
Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach. Current topics in behavioral neurosciences, 2022, Volume: 56 Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2022
Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes. Journal of psychopharmacology (Oxford, England), 2022, Volume: 36, Issue:1 Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Female; Hallucinogens; Health Surveys; Humans; Male; Middle Aged; N-Methyl-3,4-methylenedioxyamphetamine; Patient Acuity; Psilocybin; Substance-Related Disorders; United States; Young Adult	2022
Psychedelic-assisted psychotherapy for the treatment of major depression: a synthesis of phenomenological explanations. Medicine, health care, and philosophy, 2022, Volume: 25, Issue:2 Topics: Depression; Depressive Disorder, Major; Hallucinogens; Humans; Psilocybin; Psychotherapy	2022
How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework. Psychopharmacology, 2022, Volume: 239, Issue:6 Topics: Antidepressive Agents; Depressive Disorder, Major; Hallucinations; Hallucinogens; Humans; Lysergic Acid Diethylamide; Psilocybin; Surveys and Questionnaires	2022
Assessment of Bioactivity-Modulating Pseudo-Ring Formation in Psilocin and Related Tryptamines. Chembiochem : a European journal of chemical biology, 2022, 07-05, Volume: 23, Issue:13 Topics: Depressive Disorder, Major; Hallucinogens; Humans; Prodrugs; Psilocybin; Tryptamines	2022
Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes. Journal of psychopharmacology (Oxford, England), 2023, Volume: 37, Issue:1 Topics: Adult; Depressive Disorder, Major; Ethnicity; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybin	2023
Characterization of the Gateway Decarboxylase for Psilocybin Biosynthesis. Chembiochem : a European journal of chemical biology, 2022, 12-16, Volume: 23, Issue:24 Topics: Biological Products; Carboxy-Lyases; Depressive Disorder, Major; Humans; Psilocybin; Pyridoxal Phosphate	2022
A Case of Prolonged Mania, Psychosis, and Severe Depression After Psilocybin Use: Implications of Increased Psychedelic Drug Availability. The American journal of psychiatry, 2022, 12-01, Volume: 179, Issue:12 Topics: Depression; Depressive Disorder, Major; Hallucinogens; Humans; Mania; Psilocybin; Psychotic Disorders	2022
Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients. Journal of affective disorders, 2023, 02-15, Volume: 323 Topics: Depressive Disorder, Major; Hallucinogens; Humans; Neoplasms; Psilocybin; Self Report	2023
Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation. Journal of affective disorders, 2023, 04-01, Volume: 326 Topics: Anxiety; Depressive Disorder, Major; Hallucinogens; Humans; Obsessive-Compulsive Disorder; Psilocybin	2023
Psilocybin for Treatment-Resistant Depression. The New England journal of medicine, 2023, Feb-23, Volume: 388, Issue:8 Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2023
Psilocybin for Treatment-Resistant Depression. The New England journal of medicine, 2023, Feb-23, Volume: 388, Issue:8 Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2023
Psilocybin for Treatment-Resistant Depression. The New England journal of medicine, 2023, Feb-23, Volume: 388, Issue:8 Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2023
Psilocybin for Treatment-Resistant Depression. Reply. The New England journal of medicine, 2023, Feb-23, Volume: 388, Issue:8 Topics: Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2023
Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder. JAMA oncology, 2023, Jun-01, Volume: 9, Issue:6 Topics: Depression; Depressive Disorder, Major; Humans; Neoplasms; Patients; Psilocybin	2023
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression. Journal of psychopharmacology (Oxford, England), 2023, Volume: 37, Issue:7 Topics: Clinical Trials as Topic; Depression; Depressive Disorder, Major; Escitalopram; Humans; Psilocybin; Psychiatric Status Rating Scales; Reproducibility of Results	2023
Why didn't the TGA consult with Australian researchers and clinicians with experience in psilocybin-assisted psychotherapy for treatment-resistant major depressive disorder? The Australian and New Zealand journal of psychiatry, 2023, Volume: 57, Issue:7 Topics: Australia; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin; Psychotherapy	2023
Psychedelics: Threshold of a Therapeutic Revolution. Neuropharmacology, 2023, Sep-15, Volume: 236 Topics: Anxiety; Depressive Disorder, Major; Hallucinogens; Humans; Psilocybin; Substance-Related Disorders	2023
HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer. Journal of pain and symptom management, 2023, Volume: 66, Issue:3 Topics: Depressive Disorder, Major; Humans; Neoplasms; Pilot Projects; Psilocybin; Psychotherapy, Group	2023
Next generation antidepressants with novel mechanisms for treatment resistant depression. Progress in brain research, 2023, Volume: 278 Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Hallucinogens; Humans; Psilocybin	2023
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA, 2023, 09-05, Volume: 330, Issue:9 Topics: Adult; Depressive Disorder, Major; Female; Hallucinogens; Humans; Male; Mental Health; Niacin; Psilocybin	2023
Scalable Hybrid Synthetic/Biocatalytic Route to Psilocybin. Chemistry (Weinheim an der Bergstrasse, Germany), 2020, Jul-02, Volume: 26, Issue:37 Topics: Agaricales; Biocatalysis; Depressive Disorder, Major; Humans; Psilocybe; Psilocybin; Tryptamines	2020
Psilocybin-Assisted Supportive Psychotherapy in the Treatment of Major Depression-Quo Vadis? JAMA psychiatry, 2021, 05-01, Volume: 78, Issue:5 Topics: Depression; Depressive Disorder, Major; Humans; Psilocybin; Psychotherapy	2021
Effects of a single dose of psilocybin on behaviour, brain 5-HT European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2021, Volume: 42 Topics: Animals; Brain; Depressive Disorder, Major; Female; Gene Expression; Hallucinogens; Psilocybin; Receptor, Serotonin, 5-HT2A; Swine	2021
Errors in a Response Rate and in Effect Sizes in Study of Psilocybin-Assisted Therapy for Major Depressive Disorder. JAMA psychiatry, 2021, 05-01, Volume: 78, Issue:5 Topics: Depressive Disorder, Major; Humans; Psilocybin; Treatment Outcome	2021
Magic mushroom compound is a potential treatment for patients with major depression. Nursing standard (Royal College of Nursing (Great Britain) : 1987), 2016, Jun-08, Volume: 30, Issue:41 Topics: Agaricales; Depressive Disorder, Major; Hallucinogens; Humans; London; Magnetic Resonance Imaging; Psilocybin	2016
The fibrinolytic system: A new target for treatment of depression with psychedelics. Medical hypotheses, 2017, Volume: 100 Topics: Animals; Antidepressive Agents; Brain; Depressive Disorder, Major; Fibrinolysin; Fibrinolysis; Hallucinogens; Humans; Inflammation; Ketamine; Models, Theoretical; Neuropeptides; Neuroserpin; Plasminogen Activator Inhibitor 1; Psilocybin; Receptor, Serotonin, 5-HT2A; Receptors, Urokinase Plasminogen Activator; Serpins; Tissue Plasminogen Activator; United States; Urokinase-Type Plasminogen Activator	2017